Latest NSCLC Stories
Protocol Amended to Provide Faster Assessment of Survival Outcomes with Reduced Trial Size BOTHELL, Wash.
- 60 percent of surveyed U.S.
- Data support VAL-083's importance as a potential therapy for non-small cell lung cancer (NSCLC), including drug-resistant NSCLC - VANCOUVER, British Columbia and MENLO PARK, Calif.,
GENEVA, April 17, 2015 /PRNewswire/ -- ASSESS shows plasma circulating tumour DNA (ctDNA) testing for EGFR mutation is a viable alternative
Alexander Chi, MD, a thoracic radiation oncologist at West Virginia University, is the principal investigator in the study of novel treatment approaches for non-small cell lung cancer.
A new study from the RSSearch® Patient Registry, the largest patient registry dedicated to radiosurgery and stereotactic body radiotherapy (SBRT), describes treatment management practices
Study Seeks to Confirm a High Response Rate among Cancer Patients with MET and Axl Genetic Alterations SAN DIEGO, Dec. 23, 2014 /PRNewswire/ -- Mirati Therapeutics, Inc.
Frontier Pharma - NSCLC - Identifying and Commercializing First-in-Class Innovation in Non-Small-Cell Lung Carcinoma provides information on pricing, market analysis, shares, forecast, and company
LUGANO, Switzerland, October 30, 2014 /PRNewswire/ -- In ROMANA 1, a pivotal Phase III study, anamorelin was shown to increase lean body mass and body weight, reduce fatigue
Launch of Four Novel Immune Checkpoint Inhibitors Will Be the Major Driver of Growth, According to Findings from Decision Resources Group BURLINGTON, Mass., Oct.